Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Pharmaceutical Preparations · Palm Beach Gardens, FL
Our rating: Neutral
Call changed from Cautious to Neutral at $307.02, moderate conviction, November 2, 2026.
Breaks if: The Neutral call turns Positive if free cash flow as a share of revenue rises above 25% for two consecutive quarterly filings — compared with roughly 18% today — confirming that the royalty model converts reported income to cash as its structure implies it should. The call turns Cautious if that same FCF margin falls below 15% for any two consecutive quarters reported before the end of 2027, or if the next annual filing shows year-on-year revenue growth below 10%; either outcome would mean a multiple pricing in real compounding cash returns is instead resting on non-cash income that does not compound.
Key figures
| Market value | $5.7B |
|---|---|
| Revenue, last 12 months | $254M |
| Net income, last 12 months | $51M |
| Free cash flow, last 12 months | $91M |
| Price to earnings | 111.5× |
| Free cash flow yield | 1.6% |
| Dividend yield | 0.0% |
| Operating margin | 10.1% |
| Return on equity | 5.4% |
| Beta to the S&P 500 | 0.97 |
| Volatility, annualized | 37.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $79M | −31.8% | $-1.43 | −$28M |
| June 30, 2026 | $64M | 33.7% | $2.22 | $24M |
| March 31, 2026 | $52M | 14.1% | $-0.67 | $48M |
| December 31, 2025 | $60M | 39.4% | $2.18 | $46M |
| September 30, 2025 | $115M | 122.8% | $5.68 | $13M |
| June 30, 2025 | $48M | 14.7% | $0.24 | $16M |
| March 31, 2025 | $45M | 46.3% | $-2.21 | −$26M |
| December 31, 2024 | $43M | 52.4% | $-1.68 | $28M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.07B: Claude 45%, Gemini 35%, Mistral 50%
- Diluted earnings per share are at least $2.18: Claude 30%, Gemini 50%, Mistral 35%
- Free cash flow for the quarter is at least $0.05B: Claude 35%, Gemini 25%, Mistral 40%
14 ledger entries and 78 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.